High-Throughput Screening of Australian Marine Organism Extracts for Bioactive Molecules Affecting the Cellular Storage of Neutral Lipids by Rae, James et al.
High-Throughput Screening of Australian Marine
Organism Extracts for Bioactive Molecules Affecting the
Cellular Storage of Neutral Lipids
James Rae
1, Frank Fontaine
2, Angela A. Salim
2, Harriet P. Lo
1, Robert J. Capon
2, Robert G. Parton
1, Sally
Martin
1*
1Division of Molecular Cell Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia, 2Division of Chemical and Structural
Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
Abstract
Mammalian cells store excess fatty acids as neutral lipids in specialised organelles called lipid droplets (LDs). Using a simple
cell-based assay and open-source software we established a high throughput screen for LD formation in A431 cells in order
to identify small bioactive molecules affecting lipid storage. Screening an n-butanol extract library from Australian marine
organisms we identified 114 extracts that produced either an increase or a decrease in LD formation in fatty acid-treated
A431 cells with varying degrees of cytotoxicity. We selected for further analysis a non-cytotoxic extract derived from the
genus Spongia (Heterofibria). Solvent partitioning, HPLC fractionation and spectroscopic analysis (NMR, MS) identified a
family of related molecules within this extract with unique structural features, a subset of which reduced LD formation. We
selected one of these molecules, heterofibrin A1, for more detailed cellular analysis. Inhibition of LD biogenesis by
heterofibrin A1 was observed in both A431 cells and AML12 hepatocytes. The activity of heterofibrin A1 was dose
dependent with 20 mM inhibiting LD formation and triglyceride accumulation by ,50% in the presence of 50 mM oleic acid.
Using a fluorescent fatty acid analogue we found that heterofibrin A1 significantly reduces the intracellular accumulation of
fatty acids and results in the formation of distinct fatty acid metabolites in both cultured cells and in embryos of the
zebrafish Danio rerio. In summary we have shown using readily accessible software and a relatively simple assay system that
we can identify and isolate bioactive molecules from marine extracts, which affect the formation of LDs and the metabolism
of fatty acids both in vitro and in vivo.
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Introduction
Fatty acids are essential components of all organisms, serving
as precursors for phospholipid synthesis, substrates for energy
production and acting as signalling molecules. Fatty acids are
stored as neutral lipids, predominantly triglycerides (TGs) and
cholesteryl esters, in intracellular organelles termed lipid droplets
(LDs) (reviewed in [1,2]). Long considered inert lipid storage
depots, LDs are now recognised as dynamic organelles with a
complex regulation. Despite the clear importance of LDs both
physiologically and pathologically very little is known about the
mechanisms underlying their biogenesis, maturation and catabo-
lism. LDs play a crucial role in maintaining the cellular levels of
lipids and cholesterol by regulating the interplay between storage
(as lipid esters), hydrolysis (lipolysis) and trafficking [2,3].
Physiologically abnormal lipid accumulation is associated with a
wide range of pathophysiological conditions including obesity,
atherosclerosis, neutral lipid storage disorders and lipodystrophies.
Despite the ubiquitous nature of LDs our understanding of their
function and regulation in most cell types is limited, and there are
currently few chemical tools available to aid our study of either the
LDs themselves or the intracellular trafficking and targeting of
fatty acids. The identification of small bioactive molecules that
can be used to manipulate triglyceride storage in cells will be
invaluable in the search for potential therapeutic agents and
therapeutic targets, and to develop small molecule reagents with
applications to basic research.
Historically, many small molecule inhibitors have been iden-
tified following extraction of metabolites from natural sources.
Over recent years a number of small molecules isolated from
natural sources have been shown to affect LD accumulation in
macrophage cells or to affect the accumulation neutral lipids
during the differentiation of model adipocyte cell lines [4–11],
both cell types in which LD formation is uniquely and specifically
regulated. As LDs are ubiquitous organelles we undertook to
develop a screen for small bioactive molecules modulating the
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in cells maintained in tissue culture can be readily manipulated by
altering the growth conditions of the cells. Growth in lipid-
depleted serum results in the loss of LDs and neutral lipids. In
contrast growth in medium containing elevated levels of free fatty
acids such as oleic acid results in the storage of neutral lipid and
the de novo formation of LDs. Both the formation and the loss of
LDs in cells can be observed microscopically using dyes that
fluoresce when present in neutral lipid environments [12]. We
have used these properties of lipid droplets in order to screen a
library of natural extracts derived from Australian marine orga-
nisms for molecules with the ability to modulate LD formation.
We established a semi-automated quantitative cell-based confocal
microscopy assay to test over 2000 extracts for effects on LD
formation and have identified a number of distinct extracts
containing potent modulators of lipid droplet metabolism. One of
these extracts was further analysed and the specific bioactive
molecular components isolated and functionally analysed both in
vitro and in vivo. These data confirmed both the suitability of the
screening approach and the presence within natural product
extracts of molecules with the potential for development as
therapeutic and/or research agents.
Materials and Methods
Ethics Statement
Zebrafish studies were carried out according to NHMRC
(Australia) guidelines and Animal Ethics Approval IMB/438/08/
NHMRC (NF) to Prof Parton.
Cell culture and reagents
A431 cells (American Type Culture Collection, Rockville, MD)
were maintained in Dulbecco’s modified Eagle’s high glucose
medium (DMEM) supplemented with 10% (v/v) fetal calf serum
(FCS) and 2 mM L-glutamine. AML12 hepatocytes were
maintained in Dulbecco’s modified Eagle’s nutrient mixture F12
medium with 10% (v/v) heat-inactivated serum supreme, 2 mM
L-glutamine, 1 mM sodium pyruvate and 0.1 mM non-essential
amino acids. Oleic acid (Calbiochem) and Bodipy-558/568 C12
(Invitrogen) were prepared as 50 mM stock solutions in ethanol.
Bodipy493/503 (Invitrogen) was prepared as a saturated stock
solution in ethanol. 49,6-diamidino-2-phenylindole (DAPI) was
prepared as a 1 mg/mL stock in water. A mixture of mono-, di-,
and triglyceride standards were used for thin-layer chromatogra-
phy (Sigma cat # 1787-1AMP). Lactate dehydrogenase levels
were measured using the Cytotoxicity Detection Kit (Roche
Diagnostics, Germany). [9,10-3H(N)]-Oleic acid was obtained
from PerkinElmer (Browns Plains, Australia). All other reagents
were from Sigma unless stated otherwise.
Delipidated fetal calf serum (DL-FCS)
FCS was delipidated using organic solvent extraction [13]. FCS,
diisopropyl ether and n-butanol (5:4:2) were homogenised using a
magnetic stirrer and centrifuged (1700 rpm for 15 min) to induce
phase separation. The lower aqueous phase was collected and re-
extracted with diisopropyl ether. Residual diisopropyl ether was
removed under a stream of nitrogen gas. DL-FCS was dialysed
(10,000 MWCO) into PBS, sterilised through 0.22 mm filter units
and stored at 220uC.
Primary assay protocol
A431 cells were plated at a density of 15,000 cells/well (100 mL)
onto black wall 96-well imaging plates (BD Falcon) in DMEM
supplemented with 10% (v/v) DL-FCS, 2 mM L-glutamine,
penicillin (100 units/mL) and streptomycin (100 mg/mL) (hereaf-
ter referred to as assay media) and allowed to adhere for 3 h. n-
Butanol extracts or sub-fractions were dried onto 96-well plates
and re-suspended in assay medium prior to horizontal transfer
(100 mL/well) into duplicate wells of cells on the imaging plate to
achieve the desired final extract concentration. Control wells
received an equivalent volume of either assay media or triacsin C.
Following incubation for 15–18 h cells were supplemented with
50 mM oleic acid for a further 8 h. At the end of the assay cells
were washed twice in PBS prior to fixation in 4% paraformalde-
hyde (PFA)/PBS for 20 min. PFA was removed and the wells
quenched with 50 mM NH4Cl/PBS, 30 min. Cells were subse-
quently co-stained with Bodipy 493/503 (0.5% v/v of saturated
solution at 20uC) and DAPI (0.1 mg/mL) for 30 min. Finally the
cells were washed twice with PBS and stored in 200 mL PBS at
4uC.
Secondary assay protocols
Purified heterofibrins were prepared at 50 mM in DMSO and
diluted in assay media to achieve the final concentrations shown in
the results section. To measure LD formation, cells were treated
with purified heterofibrins for 15–18 h prior to supplementation of
the media with 50 mM oleic acid for 8 h and processing as
described above for the primary assay. To measure the uptake and
metabolism of [
3H] oleic acid or Bodipy-558/568 C12 cells were
incubated with the relevant heterofibrins overnight as described
above. Cells were subsequently supplemented with either 50 mM
oleic acid containing 5 mCi [
3H] oleic acid or with 50 mM Bodipy-
558/568 C12 for various times as shown in the results sections.
Cells were subsequently processed for thin-layer chromatography
as detailed below, or fixed in 4% PFA/PBS for fluorescence
microscopy.
Image acquisition and analysis
Plates were imaged using a BD Pathway 855 microscope (BD
Biosciences) running Attovision 1.5/1.6 software. To measure
cell number (as a surrogate for cytotoxicity) a 162 montage epi-
fluorescent DAPI image was captured using an Olympus
UPlanSApo 10x/0,40 objective. For lipid droplet analysis single
or 162 montage confocal images were acquired for DAPI (single
optical slice) and Bodipy493/503 (collapsed Z stack) using an
Olympus VApo/340 40X/0,90 objective. Raw data images were
saved as 16 bit Tiff files for export. Image analysis was undertaken
using CellProfiler (1.0.5122) open-source software [14] (The Broad
Institute, http://www.cellprofiler.org). The image analysis pipe-
lines are detailed in supplementary data (Tables S1, S2 and S3).
Where appropriate, statistical significance was determined using a
two-tailed unpaired Student’s t-test.
Natural product extract partitioning and fractionation
Raw specimen samples were stored in ethanol at 220uC. A
detailed description of the partitioning, fractionation and subse-
quent structural analysis of specimen extracts is described in [15].
Briefly, samples in ethanol were dried by rotary evaporation and
used to prepare n-butanol partitions. The primary assay was
performed using the n-butanol extracts. Lead n-butanol extracts
containing bioactivity were further resolved by sequential par-
titioning into hexane, dichloromethane or methanol. Sub-fractions
that retained the bioactivity of the parent extract were subjected to
chemical profiling using HPLC-DAD-MS and
1H NMR and
further fractionation by preparative HPLC to isolate bioactive
molecules. Detailed structural analysis was achieved using 1D and
2D NMR and HRMS.
Inhibitors of LD Formation
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A431 cells were treated with n-butanol extracts or purified
inhibitors as described in the results sections. Cells were sub-
sequently washed with PBS, trypsinised and the cell pellet
resuspended in 0.25 mL PBS. Neutral lipids were extracted using
1 mL of methanol:chloroform (2:1) and vortexing. Following
drying under N2 and concentration, neutral lipids were redissolved
in methanol:chloroform (2:1). Lipids were loaded onto HP-TLC
silica plates and developed in hexane/diethylether/acetic acid
(70:30:1). Radiolabelled samples were developed by autoradiog-
raphy. After development plates were sprayed with a primuline
solution (50 mg/mL in acetone:water, 80:20) and visualised by
UV.
In vivo analysis of heterofibrin activity in zebrafish
Wild type zebrafish were raised as described previously [16].
Zebrafish embryos (4–6 dpf) were incubated in E3 embryo media
(5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4)
in a 12-well plate in the presence or absence of 10 mM heterofi-
brin A1 or 0.5 mM triacsin C for 2 h prior to the addition of
Bodipy558/568 C12 for 6 h. Embryos were immobilised in E3
containing tricaine (0.2% 3-aminobenzoic acid ethyl ester),
incubated on ice for 30 min, then either fixed in 4% paraformal-
dehyde in PBS overnight or homogenised in 200 mL E3 for lipid
extraction. Fixed embryos were mounted on concave slides and
imaged using an Olympus SZX-12 stereodissecting microscope
with a DP-70 12MP colour camera. Lipid extraction for TLC was
performed as described above.
Results
An automated high throughput screen for LD formation
in A431 fibroblasts
In order to establish a cell-based high throughput screen for LD
formation several fibroblast cells lines were assessed for their
applicability for automated analysis. A431 human epidermoid
carcinoma cells were found to generate LDs of a consistent size
and number in response to 50 mM oleic acid and to lose endo-
genous LDs when cultured in delipidated serum (Fig. 1A) and were
subsequently selected as the optimal cell line for assay develop-
ment and for the primary screen. Cells were seeded in 96-well
plates and grown in medium containing delipidated serum
overnight, to establish conditions of minimal LD number. Cells
were subsequently supplemented with 50 mM oleic acid for 8 h to
promote LD biogenesis. After fixation the cells were co-stained
with Bodipy493/503 and DAPI, to identify LDs and nuclei
respectively and subsequently imaged using a BD pathway
automated confocal microscope. Nuclei were detected using
epifluorescence microscopy and the number of nuclei per field
used as a surrogate read-out in subsequent analyses for cyto-
toxicity. The LDs were detected using a confocal z-series, which
was subsequently rendered into 2-dimensions. The number of LDs
generated per cell was analysed using CellProfiler (Broad Institute
Imaging Platform [14]) and the data reported as the average
number of LDs per cell (Fig. 1B). The image analysis protocol is
detailed in Materials and Methods and the CellProfiler analysis
pipeline is available as supplementary data (Tables S1 and S2).
Maintaining A431 cells in delipidated FBS overnight effectively
reduced the number of LDs to ,5 LDs/cell and subsequent
treatment with 50 mM oleic acid for 8 h induced an ,10-fold
increase in the average number of LDs per cell.
In order to establish an assay window against which to measure
the relative effect of candidate extracts on LD formation we used
triacsin C, a potent inhibitor of long-chain acyl-CoA synthase
enzymes [17]. By inhibiting the formation of acyl-CoAs, triacsin C
prevents neutral lipid synthesis and LD formation [18]. Addition
of triacsin C overnight was found to induce a dose-dependent
reduction in the average number of LDs formed per cell during
the subsequent 8 h treatment with 50 mM oleic acid (Fig. 1C). This
result confirmed the ability of the image analysis pipeline to
reliably quantify LDs and identified the optimal concentration of
triacsin C (1 mM) used in subsequent experiments. The image
analysis pipeline could also be used to determine the distribution
curve of LDs per cell (Fig. 1D). Using this analysis we could show
that the number of LDs per cell increased with oleic acid
treatment (right shift), and showed a dose-dependent shift back to
the left with increasing concentrations of triacsin C.
To examine the underlying cytotoxicity of marine extracts on
A431 cells, we performed growth curves with an inactivated extract
(exposed to ambient light and temperature for 72 h to minimize
activecomponents).A concentrationof50 mg/mLn-butanolextract
was selected as the optimal non-toxic concentration (Fig. 1E). In
order to internally control for inter-plate variability, both triacsin C
(1 mM) and inactive extract (50 mg/mL) were routinely included on
every assay plate. These conditions were adopted as the standard
protocol for the subsequent primary assay.
Primary screen of a natural extract library from Australian
marine organisms
To identify specific bioactive molecules affecting LD formation
we followed the partitioning and fractionation protocol detailed in
Fig. 2C. We hypothesised that molecules active in the lipid
metabolism pathways would partition predominantly into organic
fractions. We therefore performed a primary screen of 2184 n-
butanol extracts derived from marine organisms collected across
Australian temperate and Antarctic ecosystems. Each extract was
tested in duplicate and both the mean number of LDs per cell and
the mean number of nuclei per field, averaged between the two
wells. A typical screening plate contained 42 randomly selected
marine extracts in addition to an inactive extract control (50 mg/
mL) together with 1 mM triacsin C to account for inter-plate
variability and matrix effects. For each well the number of LDs/
cell and the number of nuclei/field was quantified. A typical
dataset derived from 42 randomly chosen extracts (1 plate) is
shown in Fig. 2B. For each individual dataset the average number
of LDs/cell 6 SD was determined and an extract was considered
to contain potential bioactivity if the number of LDs/cell fell
outside the normal range across the plate. Potentially bioactive
extracts were verified by visually scoring to ensure the accuracy
of the results. From a primary screen of 2184 extracts at a
concentration of 50 mg/mL, a total of 87 extracts (4%) resulted in
an increased number of LDs/cell, while 27 extracts (1%) resulted
in a decrease in LD number. These results suggest that within the
screened extracts there are bioactive molecules that can either
augment or reduce LD accumulation. Similarly cytotoxicity was
assumed when the number of nuclei/field fell outside the normal
range (6SD) across the plate. Only a small proportion (3%) of the
extracts were found to affect cell number. Interestingly a high
proportion of extracts potentially exhibiting cytotoxicity also
resulted in an increase in the number of LDs detected per cell
(35%). In contrast, only 5% of extracts which were considered
cytotoxic also resulted in a decrease in LD number. Whether this
reflects a biological process such as a compensatory or protective
adaptation to the cytotoxicity of the extract is currently unknown.
A subset of n-butanol extracts containing inhibitory bioactivity
were sub-fractionated into hexane, dichloromethane or methanol,
and re-screened across a range of concentrations between
1-50 mg/mL. The effect of the sub-fractions on LD formation
Inhibitors of LD Formation
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e22868Figure 1. Assay design and validation. (A) A431 cells were maintained for 18 h in media containing either 10% FCS (FCS), 10% delipidated FCS
(delipidation) or 10% delipidated FCS supplemented with 50 mM oleic acid (oleic acid). Cells were fixed and stained for LDs using Bodipy493/503.
(B) A431 cells were maintained for 8 h in 10% delipidated FCS supplemented with 50 mM oleic acid. Following fixation cells were stained for LDs using
Bodipy493/503 (green) and nuclei (blue). Native images were obtained using a BD Pathway automated confocal microscope. CellProfiler software was
used to generate segmentation masks to identify individual nuclei, cytoplasmic area and LDs, and to subsequently generate a related LD mask, using
the analysis pipeline detailed in Materials and Methods, and Tables S1 and S2. (C, D) The ability of the automated analysis pipeline to quantify LD
formation was examined using triacsin C, a potent inhibitor of TG synthesis. A431 cells were maintained overnight in delipidated serum 6 varying
concentrations of triacsin C. Cells were subsequently supplemented with 50 mM oleic acid for 8 h. Images of fixed, labelled cells were analysed using
the CellProfiler analysis pipeline to determine both the mean number of LDs/cell ((C) mean 6 sem, n.145 cells) or the frequency distribution of cells
Inhibitors of LD Formation
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in one or more sub-fractions derived from nine n-butanol extracts
(Table 1). In most cases the highest levels of bioactivity were
identified in the hexane and/or dichloromethane fractions,
consistent with enrichment in organic inhibitors. Fig. 2D shows
the distribution of bioactivity in sub-fractions obtained from
an extract derived from a species of Spongia (Heterofibria) sp.
(designation CMB-03399, Table 1). Both the original n-butanol
extract of Spongia (Heterofibria) sp. (Table 1) and the sub-fractions
were found to inhibit LD formation (Fig. 2D) without any
detectable cytotoxicity (data not shown). We therefore selected this
extract for further analysis. As the hexane fraction contained the
containing a specific number of LDs (D). Ctrl indicates cells incubated in delipidated serum only. (E) A431 cells were incubated with varying
concentrations of inactivated generic n-butanol marine extract for 18 h. Cells were fixed, the nuclei stained using DAPI and the number of cells per
field quantified.
doi:10.1371/journal.pone.0022868.g001
Figure 2. Extract analysis and identification of heterofibrin A1. (A) LD biogenesis assay design. A431 cells were seeded for 6 h in growth
medium then transferred into delipidated medium supplemented with control reagents or experimental extracts. Following incubation for 15 h cells
were further supplemented with oleic acid for 8 h prior to fixation and processing. (B) Results obtained from a typical 96-well plate in the primary
screen. A431 cells were incubated with n-butanol marine extracts at 50 mg/mL overnight prior to supplementation with 50 mM oleic acid for 8 h. Cells
were subsequently fixed, stained for cell nuclei (DAPI) and LDs (Bodipy493/503). The average number of LDs/cell and the average number of nuclei/
field were quantified. Each point represents the average of duplicate wells treated with a single extract. Results are shown for 42 randomly chosen
extracts equivalent to one 96-well plate, and error bars represent the SD within the plate. Circled areas delineate marine extracts that change either
the number of LDs per cell or nuclei per field relative to the normal range. (C) Schematic representation of the marine extracts processing protocol.
Extract were initially partitioned between n-butanol and water. n-Butanol partitions identified as containing putative bioactive molecules were
sequentially fractionated into hexane, dichloromethane or methanol, and individual fractions analysed for their effects on LD formation. Final
resolution of the active components was achieved using HPLC-DAD-MS and NMR. (D) An n-butanol extract derived from a species of Spongia
(Heterofibria) (designation CMB-03399) was fractionated as described in (C) and the effect of derived sub-fractions on LD formation analysed at
different concentrations (n=2 separate experiments, 6 SD). DCM=dichloromethane, MeOH=methanol, n-but=n-butanol.
doi:10.1371/journal.pone.0022868.g002
Inhibitors of LD Formation
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purification.
Identification of heterofibrin A1 as a bioactive molecule
in Spongia (Heterofibria) sp. extract
To resolve individual bioactive molecules from the hexane
fraction of Spongia (Heterofibria) sp. we used HPLC-DAD-MS and
NMR spectroscopic methods. This analysis resulted in the
isolation and identification of six novel acetylenic compounds,
heterofibrins A1–A3 and B1–B3, containing the rare diyne-ene
moiety (Fig. 3A). The chemical identification methodology and
structural analysis of these molecules is described in detail in our
associated publication [15]. The ability of each of the heterofibrins
to inhibit LD biogenesis was analysed across a range of con-
centrations (Fig. 3B). Two members of the heterofibrin family of
molecules, heterofibrins A1 and B1 were found to be most effective
at inhibiting LD formation. In each case the inhibition of LD
formation was dose-dependent, with a ,60% inhibition observed
at a concentration of 20 mM in the presence of 50 mM oleic acid.
As the activities of heterofibrin A1 and B1 were similar, we
focussed on heterofibrin A1, a more abundant molecule, in
subsequent analyses. The effect of heterofibrin A1 on cell viability
was determined over a range of concentrations by measuring the
release of lactate dehydrogenase (LDH) (Fig. 3C). Heterofibrin A1
was found to be non-cytotoxic at concentrations up to 50 mM (the
maximum tested) consistent with our previous finding that none of
the heterofibrin molecules were cytotoxic at a concentration of
30 mM, determined using an MTT assay [15].
To confirm that the activity of heterofibrin A1 on LD formation
was not restricted to A431 cells, and therefore the amenity of the
screening process to identifying bioactive molecules with more
widespread applications, we examined the activity of heterofibrin
A1 on AML12 hepatocytes (Fig. 4). We selected a hepatocyte cell
line as a number of pathophysiological conditions and diseases are
associated with the abnormal accumulation of LDs in this cell
type, including the development of non-alcoholic steatohepatitis
[19] and assembly of the Hepatitis C virus [20]. AML12 cells were
incubated in varying concentrations of heterofibrin A1 or with
1 mM triacsin C, and LD formation in response to 50 mM oleic
acid analysed by confocal microscopy using the image analysis
parameters described above. Consistent with the inhibitory effect
of heterofibrin A1 on LD formation in A431 cells, there was also a
significant inhibition of LD formation in AML12 hepatocytes.
These data suggest that heterofibrin A1 affects a conserved
element(s) in the LD biogenesis pathway.
Functional analysis of heterofibrin A1 activity in A431
cells
In order to determine whether heterofibrin A1 directly affected
the biogenesis of LDs in response to oleic acid or the synthesis of
triacylglycerol (TG) we analysed TG accumulation using thin-layer
chromatography (TLC). A431 cells were incubated in delipidated
serum overnight in the presence or absence of 20 mM heterofibrin
A1. Cells were subsequently supplemented with 50 mM oleic acid
for 8 h, total neutral lipids extracted and the amount of TG
quantified following TLC (Fig. 5A). Oleic acid induced a marked
increase in the cellular TG content relative to delipidated serum.
Pre-incubation with heterofibrin A1 significantly abrogated the
accumulation of TG in response to oleic acid treatment. Quan-
titation of the images demonstrated a ,50% decrease in neutral
lipid levels relative to oleic acid alone (Fig. 5B), consistent with the
decrease in the number of LDs/cell shown in Fig. 3B, suggesting
that the reduction in LD number can be attributed to a decrease in
neutral lipid levels. To confirm an inhibition of TG synthesis we
examined the metabolism of exogenous [3H] oleic acid (Fig. 5C).
Consistent with the decrease in total TG levels we found that pre-
treatment of A431 cells with heterofibrin A1 almost completely
blocked the formation of TG. Furthermore, we observed no
accumulation of intermediates on the TG biosynthetic pathway or
radiolabelled phospholipids. From these data we hypothesise that
the target(s) of heterofibrin A1 are likely to be involved in the uptake
or early processing of fatty acids, rather than the TG biosynthetic
pathways or directly in the formation of LDs.
Effect of heterofibrin A1 on fluorescent fatty acid uptake
and metabolism in cultured cells
To investigate further the nature of the cellular targets of
heterofibrin A1 we examined both the influx and the metabolism
of a fluorescently tagged fatty acid analogue, Bodipy558/568 C12
(Fig. 6A). A431 cells were incubated overnight in delipidated
serum 620 mM heterofibrin A1. The uptake of fatty acids into the
cells was subsequently measured by the addition of 50 mM
Bodipy558/568 C12 for various times between 0–60 min. Cells
were fixed and the nuclei labelled using DAPI. We adapted the
CellProfiler image analysis pipeline to quantify the cellular
fluorescence intensity using the cytoplasmic mask (Fig. 6B, Table
S3) and calculated the integrated cytoplasmic intensity of Bodipy
558/568 fluorescence/cell (Fig. 6C). We noted that under these
conditions there was little detectable cytosolic fatty acid but
significant Bodipy558/568 C12 fluorescence was incorporated into
reticular intracellular membranes, particularly in the perinuclear
Table 1. Screening of sub-fractions derived from a subset of inhibitory n-butanol extracts.
Extract ID n-Butanol extract effect Sub-fractions with confirmed activity Cytotoxicity of sub-fractions
CMB-03399 Inhibition Hexane, DCM nd
CMB-01523 Inhibition Hexane, DCM nd
CMB-01550 Inhibition Hexane, DCM nd
CMB-02242 Inhibition Hexane, DCM, Methanol nd
CMB-01081 Inhibition Hexane, DCM .1 mg/mL
CMB-03450 Inhibition DCM .1 mg/mL
CMB-02727 Inhibition DCM, Methanol DCM.1 mg/mL
CMB-03361 Inhibition Hexane, DCM Hexane.25 mg/mL DCM.5 mg/mL
CMB-01180 Augmentation Hexane, DCM .5 mg/mL
nd=no detectable cytotoxicity at 50 mg/mL.
doi:10.1371/journal.pone.0022868.t001
Inhibitors of LD Formation
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PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e22868area of the cell (Fig. 6B). At later time points small punctate dots
were also detected, predicted to be nascent LDs (results not
shown). In both the control and the heterofibrin A1-treated cells
there was a rapid initial accumulation of Bodipy558/568 C12 that
reached a plateau at ,10 min. However, in the presence of
heterofibrin A1 both the initial rate of fatty acid accumulation and
the maximal levels of fatty acids in the cell were significantly
reduced consistent with a partial inhibition of uptake of the
fluorescent fatty acid analogue.
Previous studies have shown that fluorescently labelled fatty
acids can be metabolised by mammalian cells, albeit with altered
characteristics to radiolabelled fatty acids [21,22]. As some
fluorescent fatty acid was taken up by cells pre-treated with
heterofibrin A1, we used Bodipy558/568 C12 to further examine
the metabolism of this labelled fatty acid in A431 cells in the
presence or absence of heterofibrin A1. A431 cells were incubated
6 varying concentrations of heterofibrin A1 or triacsin C
overnight and subsequently incubated in 50 mM Bodipy558/568
C12 for 2 h. At the end of the incubation period the cells were
harvested, the neutral lipids extracted and subsequently resolved
by thin-layer chromatography (TLC) (Fig. 6D). Metabolites of
Bodipy558/568 C12 were detected by their intrinsic fluorescence.
Figure 3. Effect of heterofibrins on LD formation. (A) A family of related diyne-ene fatty acids designated heterofibrin A1–A3 and B1–B3 were
isolated from the hexane fraction of Spongia (Heterofibria) sp. A detailed structural analysis of the identification of the heterofibrin family of molecules
is described in [15]. (B) The activity of six heterofibrins on LD formation was analysed in A431 cells. Each heterofibrin was analysed across a range of
concentrations. The highest levels of activity were associated with heterofibrins A1 and B1 (mean 6 sem, n=4 separate experiments). (C) The effect
of heterofibrin A1 on cell viability was analysed by measuring LDH release. Cells were incubated for 16 h in control medium, DMSO, 50 mM oleic acid
or varying concentrations of heterofibrin A1 (Hf-A1). At the end of the incubation period LDH activity in either the media or in solubilised whole cell
lysates were measured according the manufacturers instructions (mean 6 sem, n=3 separate experiments).
doi:10.1371/journal.pone.0022868.g003
Figure 4. Heterofibrin A1 inhibition of LD biogenesis in AML12 hepatocytes. (A) AML12 hepatocytes were incubated overnight in
delipidated FCS supplemented with either with 1 mM triacsin C or different concentrations of heterofibrin A1. Cells were subsequently treated with
50 mM oleic acid for 8 h. Control cells were incubated in delipidated FCS only. Cells were fixed and labelled for lipid droplets (Bodipy493/503, green)
and nuclei (DAPI, blue). (B) Images of the fixed, labelled cells were analysed using the CellProfiler analysis pipeline and the number of LDs/cell
quantified (mean 6 sem, n=3 separate experiments).
doi:10.1371/journal.pone.0022868.g004
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plates with primuline. Analysis of the TLC revealed several
intriguing observations. First, despite the inhibition of fluorescent
fatty acid accumulation in intracellular membranes by heterofibrin
A1, there was only a small decrease detected in the total amount of
Bodipy558/568 C12 in the cells. Second, examination of Bodipy
558/568 C12 fluorescence revealed the accumulation of fluores-
cent metabolites in the heterofibrin A1-treated cells, resolving
between the free cholesterol and free Bodipy558/568 C12 bands
(Rf=0.23 and 0.19), that were not detected in the control cells or
in cells treated with triacsin C. A third band was resolved just
above the free cholesterol band in control cells and in heterofibrin
A1-treated cells, but not in triacsin C-treated cells suggesting the
generation of an acyl-CoA species. Interestingly, in cells treated
with 50 mM heterofibrin A1 the intensity of this band was reduced.
While analysis of radiolabelled oleic acid metabolism had
suggested that heterofibrin A1 did not directly affect enzymes
involved in TG biosynthesis, fluorescent fatty acid was both
internalised and metabolised in the presence of heterofibrin A1
albeit with altered kinetics and products. As the identification of
fluorescence fatty acid metabolites by TLC was problematic, we
examined the possibility that heterofibrin A1 directly inhibits
enzymes involved in either the neutral lipid biosynthetic pathway
(diacylglycerol acyltransferase, DGAT) or lipolysis pathway by
Figure 5. Quantification of triglyceride in A431 cells. (A) A431 cells were incubated as follows: (1) delipidated FCS 16 h, 50 mM oleic acid 8 h,
(2) delipidated FCS 24 h, (3) delipidated FCS containing 20 mM heterofibrin A1 16 h, 50 mM oleic acid 8 h. Neutral lipids were extracted and resolved
by TLC. Results are shown for two independent sets of cells. Neutral Lipid Std=45 mg lipid standard, Cholesterol Std=10 mg free cholesterol. (B) The
accumulation of TG was quantified using Image J. Results shown are relative to oleic acid (mean 6 sem, n=4 separate experiments). (C) A431 cells
were incubated in delipidated FCS containing either 20 mM heterofibrin A1 or DMSO for 16 h. Cells were subsequently supplemented with 50 mM
oleic acid containing 5 mCi [3H] oleic acid for 6 h. Neutral lipids were extracted and resolved by TLC. Results are shown for two independent sets of
cells. Neutral Lipid Std=45 mg lipid standard, Cholesterol Std=10 mg free cholesterol.
doi:10.1371/journal.pone.0022868.g005
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of heterofibrin A1 to that of a known inhibitor of DGAT, 2-
bromooctanoate [23,24], and to two pan-lipase inhibitors, E600
and orlistat [25–27] (Fig. 7). Consistent with the data shown in
Fig. 6D, heterofibrin A1 treatment resulted in the generation of
unique Bodipy558/568 C12 metabolites resolving at the level of
Figure 6. Fluorescent fatty acid uptake and metabolism in A431 cells. (A) Structure of BodipyH558/568 C12 (Invitrogen). (B) A431 cells were
incubated in delipidated FCS (control) or 20 mM heterofibrin A1 overnight. Cells were subsequently incubated with 50 mM Bodipy558/568 C12 for
30 min, fixed and cell nuclei labelled using DAPI. The accumulation of fatty acid within the cytoplasm of the cell was determined by Bodipy558/568
C12 fluorescence. Cytoplasmic and nuclear imaging masks were generated using CellProfiler and used to determine the average cytoplasmic intensity
of Bodipy558/568 C12 fluorescence per cell. (C) The fluorescence intensity of cytoplasmic Bodipy558/568 C12 was quantified at various times over a
60 min period (mean 6 sem, n=4 expts). (D) A431 cells were incubated overnight in delipidated FCS, heterofibrin A1 (Hf-A1, 20–50 mM) or triacsin C
(TrC, 0.5–1 mM), then supplemented with 50 mM Bodipy558/568 C12 for 2 h. Neutral lipids were extracted and resolved by TLC. Bodipy558/568 C12
was detected using its intrinsic fluorescence and total lipids detected using primuline. Lanes are as follows: (1) Cells incubated in 50 mM Bodipy558/
568 C12 only for 2 h, (2) Control cells incubated in delipidated FCS only, (3) Bodipy558/568 C12,2 4mg, (4) cholesterol standard, 10 mg. Arrows indicate
free cholesterol (FC) and free Bodipy558/568 C12. Arrowheads indicate Bodipy558/568 C12 metabolites detected in the heterofibrin A1 treated cells
only. Lower panels highlight regions of the TLC plate incorporating novel metabolites.
doi:10.1371/journal.pone.0022868.g006
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any of the other inhibitors. In contrast, the Bodipy558/568 C12
metabolite resolving above the cholesterol band was readily
detectable in control cells, and in the presence of lipase or DGAT
inhibitors, but was significantly reduced in heterofibrin A-treated
cells and almost absent from triacsin C-treated cells. As hetero-
fibrin A1 itself resolved higher up the silica plate with a Rf=0.42
and was not intrinsically fluorescent at the wavelength used to
detect Bodipy558/568 it is unlikely that these novel metabolites
are derived from the esterification of heterofibrin A1 (see Fig. 8B).
Theses data show that the novel metabolites of Bodipy558/568
C12 detected with heterofibrin A1 are unlikely to result from an
effect on either lipases or DGAT. However, alterations in the
metabolic processing of Bodipy558/568 C12 in the presence of
heterofibrin A1 is at least partially similar to triacsin C, suggesting
that heterofibrin A1 could also affect the formation of acyl-CoA.
Effect of heterofibrin A1 on fluorescent fatty acid uptake
and metabolism in zebrafish embryos
Finally to examine the effects of heterofibrin A1 on a model
organism we used embryos of the zebrafish, Danio rerio. The
zebrafish embryonic intestine is metabolically active [28] and can
absorb and metabolise fluorescently labelled fatty acids albeit with
varying degrees of efficiency [29]. We incubated embryos between
days 4–6 post-fertilisation with 5–10 mM heterofibrin A1 or
0.5 mM triacsin C for 2 h prior to supplementation of the media
with 10 mM Bodipy558/568 C12 for 6 h. Fixed embryos were
subsequently examined by light microscopy. In contrast to control
embryos, embryos incubated in Bodipy558/568 C12 contained
significant fluorescence throughout the embryo but concentrated
around the gut region consistent with the ingestion of fluorescent
fatty acid (Fig. 8A). There was no detectable difference in
fluorescence intensity or distribution when the embryos were
pre-incubated with heterofibrin A1 (10 mM), triacsin C (0.5 mM)
or vehicle control (DMSO, results not shown). To investigate the
effect of heterofibrin A1 on the metabolism of Bodipy558/568 C12
in the zebrafish, we extracted neutral lipids from control or treated
embryos and analysed them by TLC. Consistent with the results of
Bodipy558/568 C12 metabolism in A431 cells, there was a similar
accumulation of unusual metabolites in the presence of hetero-
fibrin A1 in the body of the fish. These resolved with a similar
mobility to the metabolites detected in the A431 cells, between the
Bodipy558/568 C12 band and free cholesterol. These bands were
not detected when the embryos was incubated in 0.5 mM triacsin
C or with vehicle alone (DMSO) (Fig. 8B). While the nature of
these metabolites is currently unknown, the results of the
Bodipy558/568 C12 analysis suggest that a similar process is
affected by heterofibrin A1 treatment in both cultured cells and in
a model organism.
Discussion
The aim of this study was to develop a cell-based high
throughput assay for LD formation in order to screen a library of
n-butanol extracts of Australian marine organisms for compounds
with the ability to increase or decrease LD accumulation. While
previous studies have identified small molecule inhibitors of LD
formation in macrophage cell lines [6–11] and affecting the
differentiation of adipocytes [5] we are unaware of any screens
utilising Australian natural products. The Australian marine
environment is a rich source of biodiversity, a fraction of which
is held in the natural extracts collection at the Institute for
Molecular Bioscience at The University of Queensland. We have
utilised this extract collection to show that a relatively simple assay
in a model cell line can be used to identify inhibitory molecules
with conserved functional activity in less tractable cell lines and in
vivo in a model organism. Furthermore, by using sub-fractionation
and HPLC-MS we have been able to isolate specific bioactive
molecules from relatively crude n-butanol extracts. While we have
focussed in the current study on the heterofibrin family of
molecules isolated from Spongia (Heterofibria) sp., bioactivity was also
identified in a number of other marine extracts. Further analyses
of these extracts are predicted to yield more novel molecular
species with activity against LD formation and neutral lipid
accumulation (Table 1).
Figure 7. Effect of inhibitors of lipolysis and neutral lipid synthesis on fluorescent fatty acid metabolism: comparison to
heterofibrin A1. A431 cells were incubated overnight in delipidated FCS supplemented with either heterofibrin A1 or known inhibitors of neutral
lipid metabolic pathways, then supplemented with 50 mM Bodipy558/568 C12 for 2 h (lanes 2–9). Neutral lipids were extracted and resolved by TLC.
Bodipy558/568 C12 was detected using its intrinsic fluorescence and total lipids detected using primuline. Lanes are as follows: (1) cholesterol
standard, 10 mg, (2) 50 mM heterofibrin A1, (3) 20 mM heterofibrin A1, (4) 1 mM triacsin C, (5) 50 mM Orlistat, (6) 100 mM E600, (7) 600 mM 2-bromo
octanoate, (8) Bodipy558/568 C12 2 h, (9) Control cells, (10) Bodipy558/568 C12 control. Arrows (right) indicate free cholesterol (FC) and Bodipy558/
568 C12. Arrowheads (left) indicate Bodipy558/568 C12 metabolites detected in the heterofibrin A1 treated cells only. Lower panels highlight regions
of the TLC plate incorporating novel metabolites following prolonged exposure.
doi:10.1371/journal.pone.0022868.g007
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(Heterofibria) sp. are novel diyne-ene fatty acids with either a
carboxylic acid head group or the related monolactyl or dilactyl
ester (Fig. 3A; [15]). As only the carboxylic acid heterofibrins A1
and B1 significantly inhibit LD formation in A431 cells, it is likely
that the structure of the headgroup is important in the biological
activity. Conjugated diyne-ene lipids are relatively rare among
marine metabolites and are more common in the terrestrial
natural products literature. Exocarpic acid, isolated from several
plants of the family Santalaceae and Olacaceae [30] is a
regioisomer of heterofibrin A1. While exocarpic acid has yet to
be attributed biological activity, it is noteworthy that the related
plant metabolite xymenynic acid has been reported to inhibit
lipoxygenase and prostaglandin synthetase [31] and modify the
fatty acid composition of mouse adipose tissue [32]. Further
analysis of the heterofibrins will aid in identification of the cellular
targets of these molecules.
LDs are ubiquitous organelles that play a crucial role in
maintaining the cellular levels of lipids by regulating the interplay
between lipid storage and release [1,2]. Changes in LD formation
and catabolism are associated with a wide range of metabolic
disorders, genetic diseases and pathogen infection. Excessive LD
accumulation is a hallmark of some of the most prevalent con-
temporary metabolic disorders including obesity [33], hepatic
steatosis [19] and atherosclerosis [34]. As traditional dietary
approaches are having little effect on controlling weight gain, there
is increased interest in understanding the molecular regulation of
triglyceride storage in order to identify pharmaceutical targets for
controlling lipid storage and handling by cells [35]. In addition to
the physiological importance of regulating LDs in lipid metabo-
lism, pathogens such as members of the Flaviviridae family of
positive strand RNA viruses, including hepatitis C virus and
Dengue virus, induce LD formation and utilise LDs for viral
assembly [20,36]. Despite the very obvious importance of LDs in
many aspects of human disease, fundamental questions regarding
their cell biology remain unanswered. Identifying small molecules
with bioactivity affecting LD formation or catabolism will aid in
our understanding of the cellular processes underlying a variety of
pathophysiological disorders. While studies aimed at identifying
the cellular target(s) of heterofibrin A1 are ongoing, the unique
fluorescent fatty acid metabolites generated suggest a mechanism
of action distinct to inhibition of neutral lipid lipases or DGAT.
Furthermore, partial similarity to triacsin C suggests that hetero-
fibrin A1 may have more than one intracellular target. Analyses of
Figure 8. Metabolism of fluorescent fatty acid in zebrafish embryos. Zebrafish embryos (day 4–6 post-fertilisation) were incubated in the
presence or absence of 10 mM heterofibrin A1 or 0.5 mM triacsin C for 2 h prior to the addition of Bodipy558/568 C12 for 6 h. Control embryos were
incubated with vehicle (DMSO) only. Embryos were subsequently processed for fluorescence microscopy or TLC. (A) Embryos were fixed and
fluorescent fatty acid imaged using a stereo dissecting microscope. (B) Embryos were homogenised, neutral lipids extracted and resolved using TLC.
Total lipids were visualised using primuline and metabolised Bodipy558/568 C12 was detected by intrinsic fluorescence. The treatments were as
follows: Lane 1, 0.5 mM triacsin C + Bodipy 558/568 C12; lane 2, 5 mM heterofibrin A1 + Bodipy 558/568 C12; lane 3, 10 mM heterofibrin A1 + Bodipy
558/568 C12; lane 4, Bodipy 558/568 C12; lane 5, DMSO + Bodipy 558/568 C12; lane 6 no treatment. Control lanes contained 65 mg heterofibrin A1,
10 mg cholesterol, 45 mg lipid standards and 24 mg Bodipy558/568 C12. Arrows delineate triglycerides (TG), free cholesterol (FC) and Bodipy558/568
C12. Arrowheads indicate Bodipy558/568 C12 metabolites accumulated in embryos in the presence of heterofibrin A1. Lower panels highlight regions
of the TLC plate incorporating novel metabolites.
doi:10.1371/journal.pone.0022868.g008
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PLoS ONE | www.plosone.org 12 August 2011 | Volume 6 | Issue 8 | e22868the LD proteome (reviewed in [37]) and RNAi-based screening in
yeast [38–40] and drosophila [41] have demonstrated that the
regulation of LDs is highly integrated into other cell biological
processes including membrane trafficking, cell signalling and
metabolic pathways. Historically the use of small molecule
inhibitors has proven invaluable in dissecting these cell biological
processes. The identification of small molecules with bioactivity
targeting regulatory proteins in the LD biogenesis and catabolism
pathways will further understanding of this important cellular
organelle.
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